Clinical Trials · NCT00332696

Octreotide Compared to Placebo in Patients With Inoperable Bowel Obstruction Due to Peritoneal Carcinomatosis

CompletedPhase 2Octreotide (Approved)
Phase
Phase 2
Recruitment status
Completed
Sponsor
Novartis Pharmaceuticals
Enrollment
64
Start date
Sep 2005
Locations
1 site, France
Primary endpoint
Number of Participants With Treatment Success From Day 10 to Day 13
View Octreotide compound reference